Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics

References

• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHFariesDEZhuBErnstFRSwartzMSSwansonJWMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry200667345346016649833
   PubMed Web of Science ®Google Scholar
• LawMRSoumeraiSBRoss-DegnanDAdamsASA longitudinal study of medication nonadherence and hospitalization risk in schizophreniaJ Clin Psychiatry2008691475318312037
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophrenia [published correction appears in N Engl J Med. 2010;363(11):1092–1093]N Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• MueserKTMcGurkSRSchizophreniaLancet200436394262063207215207959
   PubMed Web of Science ®Google Scholar
• DavisJMMatalonLWatanabeMDBlakeLMetalonLDepot antipsychotic drugs. Place in therapyDrugs19944757417737520856
   PubMed Web of Science ®Google Scholar
• PatelMXTaylorMDavidASAntipsychotic long-acting injections: mind the gapBr J Psychiatry Suppl200952S1419880911
   PubMedGoogle Scholar
• RosenheckRAKrystalJHLewRCSP555 Research GroupLong-acting risperidone and oral antipsychotics in unstable schizophreniaN Engl J Med2011364984285121366475
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trialsSchizophr Res20111271–3839221257294
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• WestJCMarcusSCWilkJCountisLMRegierDAOlfsonMUse of depot antipsychotic medications for medication nonadherence in schizophreniaSchizophr Bull2008345995100118093962
   PubMed Web of Science ®Google Scholar
• HeresSReichhartTHamannJMendelRLeuchtSKisslingWPsychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophreniaEur Psychiatry201126529730120570493
   PubMed Web of Science ®Google Scholar
• HeresSHamannJKisslingWLeuchtSAttitudes of psychiatrists toward antipsychotic depot medicationJ Clin Psychiatry200667121948195317194274
   PubMed Web of Science ®Google Scholar
• CiudadASanLBernardoMRelapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophreniaProg Neuropsychopharmacol Biol Psychiatry2011
   Web of Science ®Google Scholar
• AmadorXFFlaumMAndreasenNCAwareness of illness in schizophrenia and schizoaffective and mood disordersArch Gen Psychiatry199451108268367944872
   PubMed Web of Science ®Google Scholar
• HoganTPAwadAGEastwoodRA self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validityPsychol Med19831311771836133297
   PubMed Web of Science ®Google Scholar
• Cannon-SpoorHEPotkinSGWyattRJMeasurement of premorbid adjustment in chronic schizophreniaSchizophr Bull1982834704847134891
   PubMed Web of Science ®Google Scholar
• Clinical global impressionGuyWECDEU Assessment Manual for Psychopharmacology, RevisedRockville MDNational Institute for Mental Health1976217222
   Google Scholar
• Oliva-MorenoJLópez-BastidaJOsuna-GuerreroRMontejo-GonzálezALDuque-GonzálezBThe costs of schizophrenia in SpainEur J Health Econ20067318218816850333
   PubMedGoogle Scholar
• Colleges of Pharmacists Spanish CouncilOfficial medicines catalog https://botplusweb.portalfarma.com/Accessed December 15, 2010
   Google Scholar
• Vázquez-PoloFJNegrínMCabasésJMSánchezEHaroJMSalvador-CarullaLAn analysis of costs of treating schizophrenia in Spain: a hierarchical Bayesian approachJ Ment Health Policy Econ20058315316516278503
   PubMed Web of Science ®Google Scholar
• Oblikue Consulting SLOblikue Consulting eSALUD – Healthcare database on costs2008 http://oblikue.com/bddcostesAccessed November 24, 2010
   Google Scholar
• ShiLAscher-SvanumHZhuBFariesDMontgomeryWMarderSRCharacteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaPsychiatr Serv200758448248817412849
   PubMed Web of Science ®Google Scholar
• KeithSJKaneJMTurnerMConleyRRNasrallahHAAcademic highlights: guidelines for the use of long-acting injectable atypical antipsychoticsJ Clin Psychiatry200465112013114744181
   PubMed Web of Science ®Google Scholar
• KelinKBrnabicAJNewtonRBaseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherencePatient Prefer Adherence2010430131120859457
   PubMed Web of Science ®Google Scholar
• HeresSHamannJMendelRIdentifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysisProg Neuropsychopharmacol Biol Psychiatry20083281987199318948163
   PubMed Web of Science ®Google Scholar
• Janssen-CilagRisperdal-ConstaSummary of Product Characteristics http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Risperdal_Consta/human_referral_000027.jsp&murl=menus/regulations/regulations.jspAccessed February 16, 2011
   Google Scholar
• EerdekensMVan HoveIRemmerieBMannaertEPharmacokinetics and tolerability of long-acting risperidone in schizophreniaSchizophr Res20047019110015246468
   PubMed Web of Science ®Google Scholar
• TaylorDPsychopharmacology and adverse effects of antipsychotic long-acting injections: a reviewBr J Psychiatry200919552S1319
   Web of Science ®Google Scholar
• TaylorDMirSMaceSWhiskeyECo-prescribing of atypical and typical antipsychotics – prescribing sequence and documented outcomePsychiatr Bull2002265170172
   Google Scholar
• PeuskensJOlivaresJMPecenakJTreatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countriesCurr Med Res Opin201026350150920014981
   PubMed Web of Science ®Google Scholar
• PatelMXDe ZoysaNBernadtMDavidADepot and oral antipsychotics: patient preferences and attitudes are not the same thingJ Psychopharmacol200923778979618583438
   PubMed Web of Science ®Google Scholar
• PatelMXNikolaouVDavidASPsychiatrists’ attitudes to maintenance medication for patients with schizophreniaPsychol Med2003331838912537039
   PubMed Web of Science ®Google Scholar
• PatelMXDavidASWhy aren’t depot antipsychotics prescribed more often and what can be done about it?Adv Psychiatr Treat2005113203211
   Google Scholar
• CaroliFRaymondetPIzardIPlasJGallBDelgadoAOpinions of French patients with schizophrenia regarding injectable medicationPatient Prefer Adherence2011516517121573047
   PubMed Web of Science ®Google Scholar
• WaddellLTaylorMAttitudes of patients and mental health staff to antipsychotic long-acting injections: systematic reviewBr J Psychiatry Suppl200952S435019880916
   PubMedGoogle Scholar
• BurnsTKnowledge about antipsychotic long-acting injections: bridging that gapBr J Psychiatry Suppl200952S5619880917
   PubMedGoogle Scholar
• OlivaresJMRodriguez-MartinezABuronJAAlonso-EscolanoDRodriguez-MoralesACost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in SpainAppl Health Econ Health Policy200861415318774869
   PubMedGoogle Scholar
• Ascher-SvanumHZhuBFariesDEThe cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry201010220059765
   PubMed Web of Science ®Google Scholar